+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Placenta Growth Factor - Pipeline Review, H1 2020

  • ID: 5027051
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 88 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Alteogen Inc
  • Cinnagen Co
  • Coherus BioSciences Inc
  • Huons Global Co Ltd
  • Lupin Ltd
  • PharmAbcine Inc
  • MORE
Placenta Growth Factor - Pipeline Review, H1 2020

Summary

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 21 molecules. The latest report Placenta Growth Factor - Pipeline Review, H1 2020, outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast. The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 6, 6, 4 and 5 respectively.

Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Wet (Neovascular / Exudative) Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Central Retinal Vein Occlusion, Choroidal Neovascularization, Age Related Macular Degeneration, Branch Retinal Vein Occlusion, Corneal Neovascularization, Metastatic Colorectal Cancer, Myopia, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy, Retinal Vein Occlusion, Retinopathy, Retinopathy Of Prematurity and Uveal Melanoma.

Furthermore, this report also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
  • The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Alteogen Inc
  • Cinnagen Co
  • Coherus BioSciences Inc
  • Huons Global Co Ltd
  • Lupin Ltd
  • PharmAbcine Inc
  • MORE
  • Introduction
  • Report Coverage
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Overview
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Companies Involved in Therapeutics Development
  • Alteogen Inc
  • Amgen Inc
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd
  • Cinnagen Co
  • Clover Biopharmaceuticals
  • Coherus BioSciences Inc
  • Formycon AG
  • Gene Techno Science Co Ltd
  • Huons Global Co Ltd
  • i2 Pharmaceuticals Inc
  • Lupin Ltd
  • Luye Pharma Group Ltd
  • Momenta Pharmaceuticals Inc
  • PharmAbcine Inc
  • Regeneron Pharmaceuticals Inc
  • Samsung Bioepis Co Ltd
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Drug Profiles
  • aflibercept - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aflibercept SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • conbercept - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KH-906 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SL-186 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SL-188 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ziv-aflibercept - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ziv-aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Dormant Products
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Discontinued Products
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Product Development Milestones
  • Featured News & Press Releases
  • Apr 08, 2020: Bayer launches pre-filled syringe to administer eye medication Eylea in Europe
  • Feb 10, 2020: Bayer announces Phase III trials with new aflibercept 8mg formulation
  • Feb 10, 2020: Regeneron reports two-year diabetic retinopathy data of Eylea
  • Jan 23, 2020: Bayer submits application to European Medicines Agency for pre-filled syringe to administer eye medication Eylea
  • Aug 13, 2019: Last trial OKed for Eylea to prevent blindness in premature infants
  • Aug 13, 2019: FDA approves Eylea (AFLIBERCEPT) prefilled syringe
  • Jun 21, 2019: Bayer initiates phase III trial of Aflibercept to prevent blindness in premature infants
  • May 22, 2019: Alteogen obtained IND approval for a clinical trial in Korea for Eylea Biosimilar (ALT-L9)
  • May 13, 2019: Formycon provides update on FYB203
  • May 13, 2019: FDA Approves EYLEA (aflibercept) Injection for Diabetic Retinopathy
  • Apr 30, 2019: Watchful waiting reasonable for patients with Diabetic Macular Edema and good vision
  • Apr 02, 2019: LY09004 approved for clinical trials in China, Luye Pharma steps-up Global R&D Investment in Biopharma Medicines
  • Feb 28, 2019: Alteogen applies for P1 trial for Eylea biosimilar
  • Feb 09, 2019: One-year results from positive phase 3 EYLEA trial in diabetic retinopathy presented at Angiogenesis Symposium
  • Jan 21, 2019: New anti-VEGF agent shows promising durability
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Information
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Alteogen Inc, H1 2020
  • Pipeline by Amgen Inc, H1 2020
  • Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H1 2020
  • Pipeline by Cinnagen Co, H1 2020
  • Pipeline by Clover Biopharmaceuticals, H1 2020
  • Pipeline by Coherus BioSciences Inc, H1 2020
  • Pipeline by Formycon AG, H1 2020
  • Pipeline by Gene Techno Science Co Ltd, H1 2020
  • Pipeline by Huons Global Co Ltd, H1 2020
  • Pipeline by i2 Pharmaceuticals Inc, H1 2020
  • Pipeline by Lupin Ltd, H1 2020
  • Pipeline by Luye Pharma Group Ltd, H1 2020
  • Pipeline by Momenta Pharmaceuticals Inc, H1 2020
  • Pipeline by PharmAbcine Inc, H1 2020
  • Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
  • Pipeline by Samsung Bioepis Co Ltd, H1 2020
  • Dormant Projects, H1 2020
  • Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Alteogen Inc
  • Amgen Inc
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd
  • Cinnagen Co
  • Clover Biopharmaceuticals
  • Coherus BioSciences Inc
  • Formycon AG
  • Gene Techno Science Co Ltd
  • Huons Global Co Ltd
  • i2 Pharmaceuticals Inc
  • Lupin Ltd
  • Luye Pharma Group Ltd
  • Momenta Pharmaceuticals Inc
  • PharmAbcine Inc
  • Regeneron Pharmaceuticals Inc
  • Samsung Bioepis Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll